Treatment of deep vein thrombosis: What factors determine appropriate treatment?

Canadian Family Physician

Volumn 51, Issue FEB., 2005, Pages 217-223

  Douketis, James D ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING TENDENCY; CLINICAL TRIAL; COMORBIDITY; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; EVIDENCE BASED MEDICINE; HOSPITAL CARE; HUMAN; LUNG EMBOLISM; MEDICAL LITERATURE; OUTPATIENT CARE; PATIENT SELECTION; THROMBOCYTOPENIA;

AMBULATORY CARE; ANTICOAGULANTS; COMORBIDITY; HOSPITALIZATION; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; VENOUS THROMBOSIS;

EID: 14044268787     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Tsai AW, Cushman M, Rosamund WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002;162(10):1182-9.
2. Hanson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. "The Study of Men Born in 1913." Arch Intern Med 1997; 157(15):1665-70.
3. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(Suppl 1):176-93S.
4. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160(2):181-8.
5. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(Suppl 1):64-94S.
6. O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999;159(19):2298-304.
7. Rodger MA, Gagne-Rodger C, Howley HE, Carrier M, Coyle D, Wells PS. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy. Thromb Res 2003;112(1-2):13-8.
8. Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334(11):682-7.
9. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334(11):677-81.
10. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337(10):657-62.
11. Schwartz T, Schmidt B, Hohlein U, Beyer J, Schroder HE, Schellong SM. Eligibility for home treatment of deep vein thrombosis: prospective study. BMJ 2001;322(7296):1212-3.
12. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158(18):2001-3.
13. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998;158(16):1809-12.
14. O'Shaughnessy D, Miles J, Wimperis J. UK patients with deep-vein thrombosis can be safely treated as out-patients. Q J Med 2000;93(10):663-7.
15. Dunn AS, Schechter C, Gotlin A, Vomvolakis D, Jacobs E, Sacks HS, et al. Outpatient treatment of deep venous thrombosis in diverse inner-city patients. Am J Med 2001;110(6):458-62.
16. Mattiasson I, Berntorp E, Bornhov S, Lagerstedt C, Lethagen S, Persson J, et al. Outpatient treatment of acute deep vein thrombosis. Int Angiol 1998;17(3):146-50.
17. Ting SB, Zeigenbein RW, Gan TE, Catalono JV, Monagle P, Silvers J, et al. Dalteparin for deep venous thrombosis: a hospital-in-the-home program. Med J Aust 1998;168(6):272-6.
18. Grau E, Real E, Pastor E, Viciano V, Aguilo J. Home treatment of deep vein thrombosis: a two-year experience of a single institution. Haematologica 1998;83(5):438-41.
19. Groce JB. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program. Pharmacotherapy 1998;18(6 Pt 3):175-80S.
20. Mathieu G, Fafard J, Cormier M, Giguère R, Nguyen DT, Dominguez M, et al. Treatment of deep vein thrombosis 1995-2000 in a Montreal university teaching hospital: from inpatient to outpatient care. Ann R Coll Physicians Surg Can 2001;34:505-8.
21. Lindmarker P, Holstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. J Intern Med 1996;240(6):395-401.
22. Merli G, Spiro TE, Olsson GG, Abildgaard U, Davidson BL, Eldor A, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134(3):191-202.
23. The Matisse Investigators. Fondaparinux compared with low-molecular-weight heparin for the initial treatment of deep vein thrombosis [abstract]. Blood 2002;100:83a.
24. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146-53.
25. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003;138(9):714-9.
26. Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160(22):3431-6.
27. Douketis JD, Kearon CB, Bates S, Duku EK, Ginsberg JS. The risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279(6):458-62.
28. Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med 2001;110(7):515-9.
29. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. Outpatient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000;83(2):209-11.
30. Wester JP, de Valk HW, Nieuwenhuis HK, Brouwer CB, van der Graaf Y, Meuwissen OJ, et al. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb Haemost 1996;76(5):682-8.
31. Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159(5):457-60.
32. Bona RD, Hickey AD, Wallace DM. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1997;78(1):137-40.
33. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000;26(Suppl 1):31-8.
34. Prandoni P, Bagatella P, Bernardi E, Girolami B, Rossi L, Scarano L, et al. Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Ann Intern Med 1998;129(4):299-302.
35. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162(16):1833-40.
36. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126(2):133-6.
37. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000;109(6):481-8.